GlassScriptPhysician profile
Derick C Adams
NPI 1558653162
$2,014.22
in general payments reported to CMS, 2019-2025
28 companies · $345 in 2025
The $345 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $60.00 · 2023: $849 · 2024: $761 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,906 · Education: $48.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,905.56 |
| Education | $48.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $267.21 | 2023-2025 | Omnipod |
| Abbvie INC. | $217.45 | 2023-2025 | Synthroid |
| Novo Nordisk INC | $165.18 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Averitas Pharma INC. | $156.30 | 2024-2025 | Qutenza |
| Medtronic, INC. | $129.11 | 2023-2024 | Minimed 780g |
| Corcept Therapeutics | $92.52 | 2023-2024 | Korlym |
| Amgen INC. | $87.65 | 2024-2025 | Evenity, Tepezza, Prolia |
| Xeris Pharmaceuticals, INC. | $83.27 | 2023 | Gvoke Hypopen |
| Ultragenyx Pharmaceutical INC. | $79.18 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $72.36 | 2023-2024 | |
| Amneal Pharmaceuticals LLC | $70.91 | 2023-2024 | Unithroid |
| Kyowa Kirin, INC. | $66.72 | 2023-2025 | Crysvita |
| Radius Health, INC. | $62.16 | 2023-2024 | Tymlos |
| Abbott Laboratories | $56.25 | 2024-2025 | Freestyle Libre 3, Freestyle Libre |
| Sanofi-Aventis U.S. LLC | $52.27 | 2023-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $49.60 | 2023 | Isturisa |
| Verity Pharmaceuticals INC. | $41.90 | 2025 | Tlando |
| Dexcom, INC. | $37.80 | 2023-2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $37.64 | 2023 | Nexletol |
| Alexion Pharmaceuticals, INC. | $36.21 | 2023 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $33.72 | 2023-2024 | |
| Antares Pharma, INC. | $21.54 | 2025 | Xyosted |
| Nevro Corp. | $20.33 | 2023 | Senza |
| Mannkind Corporation | $17.48 | 2023 | Afrezza |
| Cequr Corporation | $15.50 | 2025 | Cequr Simplicity |
| Almatica Pharma LLC | $15.42 | 2024 | Teriparatide |
| Horizon Therapeutics Plc | $14.32 | 2023 | Tepezza |
| Ascendis Pharma Endocrinology INC | $14.22 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derick Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.